IgG Immunoglobulin Replacement After CAR-T Therapy in B-cell Cancer Patients
Official title: Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
Funded at Fred Hutchinson Cancer Center · NIH-11397701 · Data updated 2026-11-12
This study tests whether giving immunoglobulin replacement after CAR-T therapy reduces infections in adults with B-cell cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $545,260 |
| NIH project number | 5R01CA276040-04 |
| Project ID | NIH-11397701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+) who have undergone CD19 CAR-T therapy and have ongoing considerations for IGRT.
✕Less likely to help
Patients who do not receive IGRT or who are not experiencing infection risk may see no direct benefit.
What this research studies
Adults who have received CD19-targeted CAR-T therapy and developed low antibody levels may receive immunoglobulin replacement to prevent infections. This trial will compare immunoglobulin replacement to a placebo to see if infections drop and to understand effects on CAR-T cell behavior and healthcare costs. The study builds on existing observations that antibody levels and infection risk are linked after CAR-T treatment, and it aims to provide clear guidance for using IGRT in this setting. Participation involves randomized assignment and close monitoring for infections, treatment effects, and resource use.
Why it matters
Potential benefit: If IGRT reduces infections without hindering CAR-T therapy, patients could experience fewer infections and potentially better overall outcomes.
How similar studies have gone: This is one of the first randomized trials specifically addressing IGRT use after CAR-T therapy; prior data are limited but suggest potential benefit and safety signals.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Hill, Joshua Aiden — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Joshua Aiden
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.